NRF2 upregulates SLC7A11, enhances GSH synthesis, and supports GPX4 activity, driving radio- and chemoresistance in cancers such as esophageal squamous cell carcinoma, clear cell renal cell carcinoma, lung adenocarcinoma, and nasopharyngeal carcinoma[55,86-88]. This evidence concerns the gene NFE2L2 and nasopharyngeal carcinoma.